On 2 April, Amylyx Pharmaceuticals, a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis, Alzheimer’s disease (AD) and other neurodegenerative diseases, announced the presentation of safety results from its Phase II PEGASUS trial at the American Academy of Neurology Annual Meeting. The PEGASUS Phase II trial was a 24-week randomised, double-blind, multi-site and placebo-controlled study evaluating the safety and tolerability of AMX0035 in people with late mild cognitive impairment or early dementia due to AD. AMX0035 is a combination of existing compounds designed to prevent neuroinflammation and nerve cell death. Findings showed that AMX0035 was safe and well tolerated. The majority of treatment-emergent adverse events associated with AMX0035 were gastrointestinal with no new safety signals identified.